These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 25574915)

  • 121. Low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern Uganda.
    Orikiriza P; Tibenderana B; Siedner MJ; Mueller Y; Byarugaba F; Moore CC; Evans EE; Bonnet M; Page AL; Bazira J; Boum Y
    PLoS One; 2015; 10(2):e0118191. PubMed ID: 25658921
    [TBL] [Abstract][Full Text] [Related]  

  • 122. Counting pyrazinamide in regimens for multidrug-resistant tuberculosis.
    Franke MF; Becerra MC; Tierney DB; Rich ML; Bonilla C; Bayona J; McLaughlin MM; Mitnick CD
    Ann Am Thorac Soc; 2015 May; 12(5):674-9. PubMed ID: 25664920
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases.
    Witney AA; Gould KA; Arnold A; Coleman D; Delgado R; Dhillon J; Pond MJ; Pope CF; Planche TD; Stoker NG; Cosgrove CA; Butcher PD; Harrison TS; Hinds J
    J Clin Microbiol; 2015 May; 53(5):1473-83. PubMed ID: 25673793
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Towards tuberculosis elimination: an action framework for low-incidence countries.
    Lönnroth K; Migliori GB; Abubakar I; D'Ambrosio L; de Vries G; Diel R; Douglas P; Falzon D; Gaudreau MA; Goletti D; González Ochoa ER; LoBue P; Matteelli A; Njoo H; Solovic I; Story A; Tayeb T; van der Werf MJ; Weil D; Zellweger JP; Abdel Aziz M; Al Lawati MR; Aliberti S; Arrazola de Oñate W; Barreira D; Bhatia V; Blasi F; Bloom A; Bruchfeld J; Castelli F; Centis R; Chemtob D; Cirillo DM; Colorado A; Dadu A; Dahle UR; De Paoli L; Dias HM; Duarte R; Fattorini L; Gaga M; Getahun H; Glaziou P; Goguadze L; Del Granado M; Haas W; Järvinen A; Kwon GY; Mosca D; Nahid P; Nishikiori N; Noguer I; O'Donnell J; Pace-Asciak A; Pompa MG; Popescu GG; Robalo Cordeiro C; Rønning K; Ruhwald M; Sculier JP; Simunović A; Smith-Palmer A; Sotgiu G; Sulis G; Torres-Duque CA; Umeki K; Uplekar M; van Weezenbeek C; Vasankari T; Vitillo RJ; Voniatis C; Wanlin M; Raviglione MC
    Eur Respir J; 2015 Apr; 45(4):928-52. PubMed ID: 25792630
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Safety and tolerability profile of second-line anti-tuberculosis medications.
    Ramachandran G; Swaminathan S
    Drug Saf; 2015 Mar; 38(3):253-69. PubMed ID: 25676682
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Patterns of HIV, TB, and non-communicable disease multi-morbidity in peri-urban South Africa- a cross sectional study.
    Oni T; Youngblood E; Boulle A; McGrath N; Wilkinson RJ; Levitt NS
    BMC Infect Dis; 2015 Jan; 15():20. PubMed ID: 25595711
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.
    Farhat MR; Mitnick CD; Franke MF; Kaur D; Sloutsky A; Murray M; Jacobson KR
    Int J Tuberc Lung Dis; 2015 Mar; 19(3):339-41. PubMed ID: 25686144
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Moxifloxacin Prophylaxis against MDR TB, New York, New York, USA.
    Trieu L; Proops DC; Ahuja SD
    Emerg Infect Dis; 2015 Mar; 21(3):500-3. PubMed ID: 25695482
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Lived experiences of patients and families with decentralised drug-resistant tuberculosis care in the Eastern Cape, South Africa.
    Iruedo JO; Pather MK
    Afr J Prim Health Care Fam Med; 2023 Dec; 15(1):e1-e16. PubMed ID: 38197684
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Cost of treatment support for multidrug-resistant tuberculosis using patient-centred approaches in Ethiopia: a model-based method.
    Rosu L; Morgan L; Tomeny EM; Worthington C; Jin M; Nidoi J; Worthington D
    Infect Dis Poverty; 2023 Jul; 12(1):65. PubMed ID: 37420269
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Cost-effectiveness of tuberculosis infection prevention and control interventions in South African clinics: a model-based economic evaluation informed by complexity science methods.
    Bozzani FM; McCreesh N; Diaconu K; Govender I; White RG; Kielmann K; Grant AD; Vassall A
    BMJ Glob Health; 2023 Feb; 8(2):. PubMed ID: 36792227
    [TBL] [Abstract][Full Text] [Related]  

  • 132. Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines.
    Gomez GB; Siapka M; Conradie F; Ndjeka N; Garfin AMC; Lomtadze N; Avaliani Z; Kiria N; Malhotra S; Cook-Scalise S; Juneja S; Everitt D; Spigelman M; Vassall A
    BMJ Open; 2021 Dec; 11(12):e051521. PubMed ID: 34862287
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Strengthening health systems to improve the value of tuberculosis diagnostics in South Africa: A cost and cost-effectiveness analysis.
    Foster N; Cunnama L; McCarthy K; Ramma L; Siapka M; Sinanovic E; Churchyard G; Fielding K; Grant AD; Cleary S
    PLoS One; 2021; 16(5):e0251547. PubMed ID: 33989317
    [TBL] [Abstract][Full Text] [Related]  

  • 134. The Discounted Money Value of Human Life Losses Associated With COVID-19 in Mauritius.
    Musango L; Nundoochan A; Kirigia JM
    Front Public Health; 2020; 8():604394. PubMed ID: 33240837
    [No Abstract]   [Full Text] [Related]  

  • 135. Informing Balanced Investment in Services and Health Systems: A Case Study of Priority Setting for Tuberculosis Interventions in South Africa.
    Bozzani FM; Sumner T; Mudzengi D; Gomez GB; White R; Vassall A
    Value Health; 2020 Nov; 23(11):1462-1469. PubMed ID: 33127017
    [TBL] [Abstract][Full Text] [Related]  

  • 136. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis.
    Marx FM; Cohen T; Menzies NA; Salomon JA; Theron G; Yaesoubi R
    Lancet Glob Health; 2020 Sep; 8(9):e1223-e1233. PubMed ID: 32827484
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: the STREAM trial.
    Madan JJ; Rosu L; Tefera MG; van Rensburg C; Evans D; Langley I; Tomeny EM; Nunn A; Phillips PP; Rusen ID; Squire SB;
    Bull World Health Organ; 2020 May; 98(5):306-314. PubMed ID: 32514196
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Responding to SARS-CoV-2 in South Africa: what can we learn from drug-resistant tuberculosis?
    Ndjeka N; Conradie F; Meintjes G; Reuter A; Hughes J; Padanilam X; Ismail N; Kock Y; Master I; Romero R; Te Riele J; Enwerem M; Ferreira H; Maartens G
    Eur Respir J; 2020 Jul; 56(1):. PubMed ID: 32471936
    [TBL] [Abstract][Full Text] [Related]  

  • 139. A Systematic Review of Methodological Variation in Healthcare Provider Perspective Tuberculosis Costing Papers Conducted in Low- and Middle-Income Settings, Using An Intervention-Standardised Unit Cost Typology.
    Cunnama L; Gomez GB; Siapka M; Herzel B; Hill J; Kairu A; Levin C; Okello D; DeCormier Plosky W; Garcia Baena I; Sweeney S; Vassall A; Sinanovic E
    Pharmacoeconomics; 2020 Aug; 38(8):819-837. PubMed ID: 32363543
    [TBL] [Abstract][Full Text] [Related]  

  • 140. "A very humiliating illness": a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa.
    Furin J; Loveday M; Hlangu S; Dickson-Hall L; le Roux S; Nicol M; Cox H
    BMC Public Health; 2020 Jan; 20(1):76. PubMed ID: 31952494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.